Prochlorperazine

Generic name: Pronounced as (proe klor per' a zeen)
Brand names
  • Compazine®
  • Compro®
  • Procomp®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 02/15/2018

Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as prochlorperazine have an increased chance of death during treatment.

Prochlorperazine is not approved by the Food and Drug Administration (FDA) for the treatment of behavior problems in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is taking prochlorperazine. For more information, visit the FDA website: http://www.fda.gov/Drugs

Prochlorperazine suppositories and tablets are used to control severe nausea and vomiting. Prochlorperazine tablets are also used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Prochlorperazine tablets are also used on a short-term basis to treat anxiety that could not be controlled by other medications. Prochlorperazine should not be used to treat any condition in children who are younger than 2 years old or who weigh less than 20 pounds (about 9 kilograms). Prochlorperazine is in a class of medications called conventional antipsychotics. It works by decreasing abnormal excitement in the brain.

Prochlorperazine comes as a tablet to take by mouth and as a suppository to place in the rectum. Prochlorperazine tablets are usually taken three to four times a day by adults and are usually given to children one to three times a day. Prochlorperazine suppositories are usually inserted twice a day. Use prochlorperazine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use prochlorperazine exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Your doctor may start you on a low dose of prochlorperazine and gradually increase your dose, not more often than once every 2-3 days.

If you are using prochlorperazine to treat schizophrenia, prochlorperazine may help control your symptoms but will not cure your condition. Continue to use prochlorperazine even if you feel well. Do not stop using prochlorperazine without talking to your doctor. If you suddenly stop using prochlorperazine, you may experience withdrawal symptoms such as nausea, vomiting, dizziness, and shakiness.

To insert a prochlorperazine suppository, follow these steps:

  1. Wash your hands thoroughly with soap and water.

  2. If the suppository is soft, hold it under cool water or place it in the refrigerator for a few minutes to harden it before removing the wrapper.

  3. Remove the wrapper, if present.

  4. If you were told to use half of the suppository, cut it lengthwise with a clean, sharp blade.

  5. Put on a finger cot or disposable glove, if desired (available at a pharmacy).

  6. Lubricate the suppository tip with a water-soluble lubricant such as K-Y Jelly, not petroleum jelly (Vaseline). If you do not have this lubricant, moisten your rectal area with cool tap water.

  7. Lie on your side with your lower leg straightened out and your upper leg bent forward toward your stomach.

  8. Lift upper buttock to expose the rectal area.

  9. Insert the suppository, pointed end first, with your finger until it passes the muscular sphincter of the rectum, about 1/2 to 1 inch (1.25 to 2.5 centimeters) in infants and 1 inch (2.5 centimeters) in adults. If not inserted past this sphincter, the suppository may pop out.

  10. Hold buttocks together for a few seconds.

  11. Remain lying down for about 15 minutes to avoid having the suppository come out.

  12. Try to avoid having a bowel movement for about an hour so that the medication in the suppository can be absorbed into the body.

  13. Discard used materials and wash your hands thoroughly.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before using prochlorperazine,

  • tell your doctor and pharmacist if you are allergic to prochlorperazine, other phenothiazines such as chlorpromazine, fluphenazine, perphenazine, promethazine (Phenergan), thioridazine, and trifluoperazine; or any other medications. If you will be taking prochlorperazine tablets, also tell your doctor if you are allergic to tartrazine (a yellow dye found in some foods and medications) or aspirin.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin); antidepressants; antihistamines; atropine (in Motofen, in Lomotil, in Lonox); barbiturates such as pentobarbital (Nembutal), phenobarbital (Luminal), and secobarbital (Seconal); diuretics ('water pills'); epinephrine (Epipen); guanethidine (not available in the US); ipratropium (Atrovent); lithium (Eskalith, Lithobid), medications for anxiety, irritable bowel disease, mental illness, Parkinson's disease, motion sickness, ulcers, or urinary problems; medications for seizures such as phenytoin (Dilantin); narcotic medications for pain; propranolol (Inderal); sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had glaucoma (condition in which increased pressure in the eye can lead to gradual loss of vision), trouble keeping your balance, seizures, an abnormal electroencephalogram (EEG; test that measures electrical activity in the brain), brain damage, pheochromocytoma (tumor on a small gland near the kidneys), breast cancer, any condition that affects the production of blood cells by your bone marrow, or heart disease. Also tell your doctor if you have ever had to stop taking a medication for mental illness due to severe side effects and if you plan to work with organophosphorus insecticides (a type of chemical used to kill insects).

  • if you will be giving prochlorperazine to a child, tell the child's doctor if the child has chickenpox, measles, a stomach virus, or an infection of the brain or spinal cord. Also tell the child's doctor if the child has any of the following symptoms: vomiting, listlessness, drowsiness, confusion, aggression, seizures, yellowing of the skin or eyes, weakness, or flu-like symptoms. Be sure to tell the child's doctor if the child has not been drinking normally, has excessive diarrhea, or appears dehydrated.

  • if you will be using prochlorperazine to treat nausea and vomiting, it is important to tell your doctor about any other symptoms you are experiencing, especially listlessness; drowsiness; confusion; aggression; seizures; headaches; problems with vision, hearing, speech, or balance; stomach pain or cramps; or constipation. Nausea and vomiting that is experienced along with these symptoms may be a sign of a more serious condition that should not be treated with prochlorperazine.

  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking prochlorperazine, call your doctor. Ptrochlorperazine may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are using prochlorperazine.

  • if you will be having a myelogram (x-ray examination of the spine), tell your doctor and the radiographer that you are taking prochlorperazine. Your doctor will probably tell you not to take prochlorperazine for 2 days before the myelogram and for one day after the myelogram.

  • you should know that this medication may make you drowsy and may affect your thinking and movements, especially at the beginning of your treatment. Do not drive a car or operate machinery until you know how this medication affects you.

  • ask your doctor about the safe use of alcohol during your treatment with prochlorperazine. Alcohol can make the side effects of prochlorperazine worse.

  • you should know that prochlorperazine may cause dizziness, especially when you get up from a lying position. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

  • you should know that prochlorperazine may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to do vigorous exercise or be exposed to extreme heat.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Prochlorperazine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • dizziness, feeling unsteady, or having trouble keeping your balance

    • blurred vision

    • dry mouth

    • stuffed nose

    • headache

    • nausea

    • constipation

    • difficulty urinating

    • widening or narrowing of the pupils (black circles in the center of the eyes)

    • increased appetite

    • weight gain

    • agitation

    • jitteriness

    • difficulty falling asleep or staying asleep

    • blank facial expression

    • drooling

    • uncontrollable shaking of a part of the body

    • shuffling walk

    • breast enlargement

    • breast milk production

    • missed menstrual periods

    • decreased sexual ability in men

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

    • fever

    • muscle stiffness

    • falling

    • confusion

    • fast or irregular heartbeat

    • sweating

    • yellowing of the skin or eyes

    • flu-like symptoms

    • sore throat, chills, and other signs of infection

    • neck cramps

    • tongue that sticks out of the mouth

    • tightness in the throat

    • difficulty breathing or swallowing

    • fine, worm-like tongue movements

    • uncontrollable, rhythmic face, mouth, or jaw movements

    • seizures

    • rash

    • hives

    • itching

    • swelling of the eyes, face, mouth, lips, tongue, throat, arms, hands, feet, ankles, or lower legs

    • vision loss, especially at night

    • seeing everything with a brown tint

    • coma (loss of consciousness for a period of time)

    • erection that lasts for hours

  • Prochlorperazine may cause other side effects. Tell your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store prochlorperazine suppositories in their wrappers; do not unwrap a suppository until just before you insert it. Store the medication at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • agitation

  • jitteriness

  • difficulty falling asleep or staying asleep

  • blank facial expression

  • drooling

  • uncontrollable shaking of a part of the body

  • shuffling walk

  • sleepiness

  • coma (loss of consciousness for a period of time)

  • seizures

  • irregular heartbeat

  • fever

  • dry mouth

  • constipation

Keep all appointments with your doctor.

Before having any laboratory test, tell your doctor and the laboratory technician that you are taking prochlorperazine.

Prochlorperazine may interfere with the results of home pregnancy tests. Talk to your doctor if you think you might be pregnant during your treatment with prochlorperazine. Do not try to test for pregnancy at home.

Do not let anyone else take or use your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Prochlorperazine.
Delavirdine Delavirdine The metabolism of Prochlorperazine can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Prochlorperazine can be decreased when combined with Nevirapine.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Dolasetron.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Prochlorperazine.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Anagrelide.
Calcium Carbonate Calcium Carbonate Calcium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Prochlorperazine.
Diphenoxylate Diphenoxylate The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Prochlorperazine.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Prochlorperazine.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.
Magnesium Hydroxide Magnesium Hydroxide Magnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Oxide Magnesium Oxide Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylergonovine Methylergonovine The metabolism of Prochlorperazine can be decreased when combined with Methylergometrine.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.
Paregoric Paregoric The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Morphine.
Penbutolol Penbutolol The serum concentration of Acebutolol can be increased when it is combined with Prochlorperazine.
Pentazocine Pentazocine The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Pentazocine.
Ranitidine Ranitidine The metabolism of Prochlorperazine can be decreased when combined with Ranitidine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.
Tacrolimus Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Prochlorperazine.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.
Triamcinolone Triamcinolone The metabolism of Prochlorperazine can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.
Doxycycline Injection Doxycycline Injection The metabolism of Prochlorperazine can be decreased when combined with Doxycycline.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Prochlorperazine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Prochlorperazine.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Prochlorperazine.
Hydromorphone Injection Hydromorphone Injection The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Hydromorphone.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meperidine.
Methylprednisolone Injection Methylprednisolone Injection The metabolism of Prochlorperazine can be increased when combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Prochlorperazine.
Morphine Injection Morphine Injection The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Morphine.
Altretamine Altretamine The risk or severity of extrapyramidal symptoms can be increased when Prochlorperazine is combined with Amphetamine.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Prochlorperazine.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Granisetron.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Prochlorperazine.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alosetron.
Dofetilide Dofetilide Prochlorperazine may decrease the excretion rate of Dofetilide which could result in a higher serum level.
Entacapone Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Prochlorperazine.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Prochlorperazine.
Orlistat Orlistat The metabolism of Prochlorperazine can be increased when combined with Orlistat.
Oxcarbazepine Oxcarbazepine The metabolism of Prochlorperazine can be increased when combined with Oxcarbazepine.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.
Anakinra Anakinra The metabolism of Prochlorperazine can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.
Linezolid Linezolid The risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Prochlorperazine.
Trimipramine Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Prochlorperazine.
Etanercept Injection Etanercept Injection The metabolism of Prochlorperazine can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Prochlorperazine can be increased when combined with Modafinil.
Tenofovir Tenofovir The metabolism of Tenofovir can be decreased when combined with Prochlorperazine.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Prochlorperazine.
Epinephrine Injection Epinephrine Injection The metabolism of Prochlorperazine can be decreased when combined with Epinephrine.
Escitalopram Escitalopram The serum concentration of Escitalopram can be increased when it is combined with Prochlorperazine.
Zonisamide Zonisamide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Prochlorperazine can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Prochlorperazine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmethylphenidate.
Atazanavir Atazanavir The metabolism of Prochlorperazine can be decreased when combined with Atazanavir.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Prochlorperazine.
Rosuvastatin Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Prochlorperazine.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Prochlorperazine.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Prochlorperazine.
Aprepitant Aprepitant The metabolism of Prochlorperazine can be decreased when combined with Aprepitant.
Memantine Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Prochlorperazine.
Tegaserod Tegaserod The metabolism of Prochlorperazine can be decreased when combined with Tegaserod.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Prochlorperazine can be increased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The therapeutic efficacy of Apomorphine can be decreased when used in combination with Prochlorperazine.
Infliximab Injection Infliximab Injection The metabolism of Prochlorperazine can be increased when combined with Infliximab.
Protriptyline Protriptyline The serum concentration of Prochlorperazine can be increased when it is combined with Protriptyline.
Rifaximin Rifaximin The metabolism of Prochlorperazine can be increased when combined with Rifaximin.
Duloxetine Duloxetine The metabolism of Duloxetine can be decreased when combined with Prochlorperazine.
Norethindrone Norethindrone The metabolism of Norethisterone can be decreased when combined with Prochlorperazine.
Trospium Trospium Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan The metabolism of Prochlorperazine can be increased when combined with Bosentan.
Cinacalcet Cinacalcet The metabolism of Prochlorperazine can be decreased when combined with Cinacalcet.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Prochlorperazine.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Eszopiclone.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Prochlorperazine.
Voriconazole Voriconazole The metabolism of Prochlorperazine can be decreased when combined with Voriconazole.
Dextroamphetamine Dextroamphetamine The risk or severity of extrapyramidal symptoms can be increased when Prochlorperazine is combined with Amphetamine.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Prochlorperazine can be decreased when combined with Peginterferon alfa-2b.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prochlorperazine.
Isocarboxazid Isocarboxazid The risk or severity of extrapyramidal symptoms can be increased when Prochlorperazine is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.
Darifenacin Darifenacin The metabolism of Darifenacin can be decreased when combined with Prochlorperazine.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fentanyl.
Pregabalin Pregabalin The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The metabolism of Prochlorperazine can be increased when combined with Deferasirox.
Tipranavir Tipranavir The metabolism of Tipranavir can be decreased when combined with Prochlorperazine.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.
Ranolazine Ranolazine The serum concentration of Prochlorperazine can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Prochlorperazine can be increased when combined with Abatacept.
Rasagiline Rasagiline The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Imatinib.
Gefitinib Gefitinib The metabolism of Prochlorperazine can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Prochlorperazine.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Paliperidone.
Bortezomib Bortezomib The metabolism of Prochlorperazine can be decreased when combined with Bortezomib.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Oxaliplatin.
Posaconazole Posaconazole The metabolism of Prochlorperazine can be decreased when combined with Posaconazole.
Primaquine Primaquine The metabolism of Prochlorperazine can be decreased when combined with Primaquine.
Bismuth Subsalicylate Bismuth Subsalicylate Prochlorperazine may increase the neurotoxic activities of Bismuth subsalicylate.
Darunavir Darunavir The metabolism of Darunavir can be decreased when combined with Prochlorperazine.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine Prochlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Prochlorperazine.
Sorafenib Sorafenib The metabolism of Prochlorperazine can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The metabolism of Prochlorperazine can be decreased when combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Prochlorperazine.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Prochlorperazine.
Mexiletine Mexiletine The metabolism of Prochlorperazine can be decreased when combined with Mexiletine.
Armodafinil Armodafinil The metabolism of Prochlorperazine can be increased when combined with Armodafinil.
Ivermectin Ivermectin The metabolism of Prochlorperazine can be increased when combined with Ivermectin.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Prochlorperazine.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Prochlorperazine.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Toremifene.
Bexarotene Bexarotene The metabolism of Prochlorperazine can be increased when combined with Bexarotene.
Budesonide Budesonide The metabolism of Prochlorperazine can be increased when combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Prochlorperazine can be decreased when combined with Chloramphenicol.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Prochlorperazine.
Etravirine Etravirine The metabolism of Prochlorperazine can be increased when combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The metabolism of Prochlorperazine can be decreased when combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desvenlafaxine.
Cevimeline Cevimeline The metabolism of Prochlorperazine can be decreased when combined with Cevimeline.
Nebivolol Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Prochlorperazine.
Pilocarpine Pilocarpine The metabolism of Prochlorperazine can be decreased when combined with Pilocarpine.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Prochlorperazine.
Certolizumab Injection Certolizumab Injection The metabolism of Prochlorperazine can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Prochlorperazine.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Prochlorperazine.
Mitotane Mitotane The metabolism of Prochlorperazine can be increased when combined with Mitotane.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.
Naltrexone Injection Naltrexone Injection The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Naltrexone.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.
Fesoterodine Fesoterodine Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Prochlorperazine.
Betaxolol Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Prochlorperazine.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Iloperidone.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lacosamide.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Prochlorperazine.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Prochlorperazine.
Dronedarone Dronedarone The metabolism of Dronedarone can be decreased when combined with Prochlorperazine.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Prochlorperazine.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Topotecan Topotecan The metabolism of Prochlorperazine can be increased when combined with Topotecan.
Golimumab Injection Golimumab Injection The metabolism of Prochlorperazine can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Pazopanib can be decreased when combined with Prochlorperazine.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Prochlorperazine.
Oxymorphone Oxymorphone The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Prochlorperazine can be increased when combined with Tocilizumab.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prochlorperazine.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Prochlorperazine.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The metabolism of Prochlorperazine can be increased when combined with Acetaminophen.
Vilazodone Vilazodone The metabolism of Vilazodone can be decreased when combined with Prochlorperazine.
Denileukin Diftitox Injection Denileukin Diftitox Injection The metabolism of Prochlorperazine can be decreased when combined with Aldesleukin.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Prochlorperazine.
Busulfan Injection Busulfan Injection The metabolism of Busulfan can be decreased when combined with Prochlorperazine.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Prochlorperazine.
Linagliptin Linagliptin The metabolism of Prochlorperazine can be decreased when combined with Linagliptin.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Prochlorperazine.
Telaprevir Telaprevir The metabolism of Prochlorperazine can be decreased when combined with Glecaprevir.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Prochlorperazine can be decreased when combined with Cyclophosphamide.
Abiraterone Abiraterone The metabolism of Prochlorperazine can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prochlorperazine.
Ticagrelor Ticagrelor The metabolism of Prochlorperazine can be decreased when combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Prochlorperazine can be decreased when combined with Brentuximab vedotin.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Prochlorperazine.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Vandetanib.
Clobazam Clobazam The metabolism of Prochlorperazine can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prochlorperazine.
Ivacaftor Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Prochlorperazine.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Prochlorperazine.
Crizotinib Crizotinib The metabolism of Crizotinib can be decreased when combined with Prochlorperazine.
Cabergoline Cabergoline The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Cabergoline.
Naloxone Injection Naloxone Injection The metabolism of Prochlorperazine can be decreased when combined with Naloxone.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.
Enzalutamide Enzalutamide The metabolism of Prochlorperazine can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The metabolism of Prochlorperazine can be decreased when combined with Mirabegron.
Regorafenib Regorafenib The metabolism of Prochlorperazine can be decreased when combined with Regorafenib.
Bosutinib Bosutinib The metabolism of Prochlorperazine can be decreased when combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The metabolism of Prochlorperazine can be increased when combined with Corticotropin.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Bedaquiline.
Alogliptin Alogliptin The metabolism of Alogliptin can be decreased when combined with Prochlorperazine.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Prochlorperazine.
Pomalidomide Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Prochlorperazine.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Prochlorperazine can be decreased when combined with Trastuzumab emtansine.
Dabrafenib Dabrafenib The metabolism of Prochlorperazine can be decreased when combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Prochlorperazine can be decreased when combined with Ospemifene.
Trametinib Trametinib The metabolism of Prochlorperazine can be increased when combined with Trametinib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Prochlorperazine.
Lomitapide Lomitapide The metabolism of Prochlorperazine can be decreased when combined with Lomitapide.
Simeprevir Simeprevir The metabolism of Prochlorperazine can be decreased when combined with Simeprevir.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Prochlorperazine.
Apremilast Apremilast The metabolism of Prochlorperazine can be increased when combined with Apremilast.
Ceritinib Ceritinib The metabolism of Ceritinib can be decreased when combined with Prochlorperazine.
Siltuximab Injection Siltuximab Injection The metabolism of Prochlorperazine can be increased when combined with Siltuximab.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eslicarbazepine.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Prochlorperazine.
Testosterone Injection Testosterone Injection The metabolism of Prochlorperazine can be increased when combined with Testosterone.
Oritavancin Injection Oritavancin Injection The metabolism of Prochlorperazine can be increased when combined with Oritavancin.
Vorapaxar Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Prochlorperazine.
Hydrocodone Hydrocodone Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Prochlorperazine.
Methamphetamine Methamphetamine Prochlorperazine may decrease the stimulatory activities of Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tasimelteon.
Lanreotide Injection Lanreotide Injection The metabolism of Prochlorperazine can be decreased when combined with Lanreotide.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Prochlorperazine.
Secukinumab Injection Secukinumab Injection The metabolism of Prochlorperazine can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.
Palbociclib Palbociclib The metabolism of Palbociclib can be decreased when combined with Prochlorperazine.
Lenvatinib Lenvatinib The metabolism of Prochlorperazine can be decreased when combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Prochlorperazine can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Prochlorperazine can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Haloperidol.
Ivabradine Ivabradine Ivabradine may increase the QTc-prolonging activities of Prochlorperazine.
Isavuconazonium Injection Isavuconazonium Injection The metabolism of Prochlorperazine can be increased when combined with Isavuconazonium.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Prochlorperazine.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Prochlorperazine can be decreased when combined with Rolapitant.
Prednisolone Prednisolone The metabolism of Prochlorperazine can be increased when combined with Prednisolone.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Prochlorperazine.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cariprazine.
Eluxadoline Eluxadoline The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Eluxadoline.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Prochlorperazine.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Prochlorperazine.
Osimertinib Osimertinib The metabolism of Prochlorperazine can be decreased when combined with Osimertinib.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Prochlorperazine.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Prochlorperazine.
Rifapentine Rifapentine The metabolism of Prochlorperazine can be increased when combined with Rifapentine.
Lesinurad Lesinurad The metabolism of Prochlorperazine can be increased when combined with Lesinurad.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The metabolism of Prochlorperazine can be decreased when combined with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Prochlorperazine can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brivaracetam.
Venetoclax Venetoclax The metabolism of Prochlorperazine can be decreased when combined with Venetoclax.
Cobicistat Cobicistat The metabolism of Prochlorperazine can be decreased when combined with Cobicistat.
Pimavanserin Pimavanserin The therapeutic efficacy of Pimavanserin can be decreased when used in combination with Prochlorperazine.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenhydramine.
Rucaparib Rucaparib The metabolism of Prochlorperazine can be decreased when combined with Rucaparib.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ribociclib.
Brigatinib Brigatinib The metabolism of Prochlorperazine can be decreased when combined with Brigatinib.
Doxepin (Insomnia) Doxepin (Insomnia) The serum concentration of Doxepin can be increased when it is combined with Prochlorperazine.
Deutetrabenazine Deutetrabenazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deutetrabenazine.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Prochlorperazine.
Deflazacort Deflazacort The metabolism of Prochlorperazine can be increased when combined with Deflazacort.
Safinamide Safinamide The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Safinamide.
Sarilumab Injection Sarilumab Injection The metabolism of Prochlorperazine can be increased when combined with Sarilumab.
Midostaurin Midostaurin The metabolism of Prochlorperazine can be increased when combined with Midostaurin.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Prochlorperazine.
Enasidenib Enasidenib The metabolism of Prochlorperazine can be decreased when combined with Enasidenib.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Prochlorperazine can be increased when combined with Fosaprepitant.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Prochlorperazine.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Prochlorperazine.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Prochlorperazine.
Acalabrutinib Acalabrutinib The metabolism of Prochlorperazine can be decreased when combined with Acalabrutinib.
Letermovir Letermovir The metabolism of Prochlorperazine can be decreased when combined with Letermovir.
Tetrabenazine Tetrabenazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrabenazine.
Buprenorphine Injection Buprenorphine Injection Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The metabolism of Prochlorperazine can be increased when combined with Apalutamide.
Fostamatinib Fostamatinib The metabolism of Prochlorperazine can be decreased when combined with Fostamatinib.
Baricitinib Baricitinib The metabolism of Baricitinib can be decreased when combined with Prochlorperazine.
Lofexidine Lofexidine The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Encorafenib.
Ivosidenib Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Prochlorperazine.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Prochlorperazine.
Tafenoquine Tafenoquine The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Prochlorperazine.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Prochlorperazine.
Dacomitinib Dacomitinib The metabolism of Prochlorperazine can be decreased when combined with Dacomitinib.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Prochlorperazine.
Stiripentol Stiripentol The metabolism of Prochlorperazine can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Glasdegib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Prochlorperazine.
Rifamycin Rifamycin The metabolism of Prochlorperazine can be increased when combined with Rifamycin.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Prochlorperazine.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Prochlorperazine can be increased when combined with Emapalumab.
Siponimod Siponimod The metabolism of Siponimod can be decreased when combined with Prochlorperazine.
Erdafitinib Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Prochlorperazine.
Alpelisib Alpelisib The metabolism of Prochlorperazine can be decreased when combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Solriamfetol.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Prochlorperazine.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Entrectinib.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Prochlorperazine.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Prochlorperazine.
Pitolisant Pitolisant The serum concentration of Prochlorperazine can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The metabolism of Prochlorperazine can be decreased when combined with Fedratinib.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Prochlorperazine.
Phenytoin Injection Phenytoin Injection The metabolism of Prochlorperazine can be increased when combined with Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection The metabolism of Prochlorperazine can be increased when combined with Fosphenytoin.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Prochlorperazine.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lasmiditan.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Prochlorperazine.
Cenobamate Cenobamate The serum concentration of Prochlorperazine can be decreased when it is combined with Cenobamate.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Prochlorperazine.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lemborexant.
Fenfluramine Fenfluramine The metabolism of Prochlorperazine can be decreased when combined with Fenfluramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Prochlorperazine.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prochlorperazine.
Pralsetinib Pralsetinib The metabolism of Prochlorperazine can be increased when combined with Pralsetinib.
Opicapone Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Prochlorperazine.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Prochlorperazine can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection Prochlorperazine may increase the neurotoxic activities of Naxitamab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Prochlorperazine.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be decreased when combined with Prochlorperazine.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol) Vitamin E (Alpha-Tocopherol) The metabolism of Prochlorperazine can be increased when combined with Vitamin E.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Prochlorperazine.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Prochlorperazine.
Sodium Bicarbonate Sodium Bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxyurea Hydroxyurea The metabolism of Prochlorperazine can be decreased when combined with Hydroxyurea.
Phenobarbital Phenobarbital The metabolism of Prochlorperazine can be increased when combined with Phenobarbital.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.
Methotrexate Injection Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Prochlorperazine.
Levorphanol Levorphanol The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Levorphanol.
Primidone Primidone The metabolism of Prochlorperazine can be increased when combined with Primidone.
Methsuximide Methsuximide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.
Diethylpropion Diethylpropion Prochlorperazine may decrease the stimulatory activities of Diethylpropion.
Chlorpromazine Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Prochlorperazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepic acid.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.
Amantadine Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Prochlorperazine.
Codeine Codeine The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Prochlorperazine.
Tranylcypromine Tranylcypromine The metabolism of Tranylcypromine can be decreased when combined with Prochlorperazine.
Phenelzine Phenelzine The risk or severity of extrapyramidal symptoms can be increased when Prochlorperazine is combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Prochlorperazine.
Ergoloid Mesylates Ergoloid Mesylates The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Prochlorperazine.
Tetracycline Tetracycline The metabolism of Prochlorperazine can be decreased when combined with Tetracycline.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.
Dapsone Dapsone The risk or severity of QTc prolongation can be increased when Dapsone is combined with Prochlorperazine.
Oxycodone Oxycodone The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.
Oxybutynin Oxybutynin The metabolism of Prochlorperazine can be decreased when combined with Oxybutynin.
Benztropine Benztropine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Prochlorperazine.
Orphenadrine Orphenadrine Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.
Phentermine Phentermine Prochlorperazine may decrease the stimulatory activities of Phentermine.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
Amoxapine Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Prochlorperazine.
Hydrocortisone Hydrocortisone The metabolism of Prochlorperazine can be increased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The metabolism of Prochlorperazine can be decreased when combined with Doxorubicin.
Carbamazepine Carbamazepine The metabolism of Carbamazepine can be increased when combined with Prochlorperazine.
Molindone Molindone The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Prochlorperazine.
Hydralazine Hydralazine The metabolism of Prochlorperazine can be decreased when combined with Hydralazine.
Cimetidine Cimetidine The metabolism of Prochlorperazine can be decreased when combined with Cimetidine.
Warfarin Warfarin The metabolism of Warfarin can be decreased when combined with Prochlorperazine.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.
Loperamide Loperamide The metabolism of Prochlorperazine can be decreased when combined with Loperamide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promethazine.
Daunorubicin Daunorubicin The metabolism of Prochlorperazine can be decreased when combined with Daunorubicin.
Griseofulvin Griseofulvin The metabolism of Prochlorperazine can be increased when combined with Griseofulvin.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Prochlorperazine.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.
Chloroquine Chloroquine The metabolism of Prochlorperazine can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Prochlorperazine can be decreased when combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.
Calcitriol Calcitriol The metabolism of Prochlorperazine can be increased when combined with Calcitriol.
Sulfinpyrazone Sulfinpyrazone The metabolism of Prochlorperazine can be increased when combined with Sulfinpyrazone.
Clindamycin Injection Clindamycin Injection Prochlorperazine may increase the neurotoxic activities of Clindamycin.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Prochlorperazine.
Amitriptyline Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Prochlorperazine.
Imipramine Imipramine The metabolism of Imipramine can be decreased when combined with Prochlorperazine.
Probenecid Probenecid The metabolism of Prochlorperazine can be increased when combined with Probenecid.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Quinidine.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Prochlorperazine.
Isoniazid Isoniazid The metabolism of Prochlorperazine can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Rifampicin can be increased when combined with Prochlorperazine.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Prochlorperazine.
Tamoxifen Tamoxifen The metabolism of Prochlorperazine can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.
Methimazole Methimazole The metabolism of Prochlorperazine can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prochlorperazine.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prochlorperazine.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Prochlorperazine.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Prochlorperazine can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Prochlorperazine.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Cyproheptadine Cyproheptadine Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The metabolism of Prochlorperazine can be decreased when combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prochlorperazine.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Prochlorperazine.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Prochlorperazine.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Prochlorperazine.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Prochlorperazine.
Danazol Danazol The metabolism of Prochlorperazine can be decreased when combined with Danazol.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Prochlorperazine.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Prochlorperazine.
Pseudoephedrine Pseudoephedrine Prochlorperazine may decrease the stimulatory activities of Pseudoephedrine.
Nortriptyline Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Prochlorperazine.
Amphotericin B Injection Amphotericin B Injection The metabolism of Prochlorperazine can be decreased when combined with Amphotericin B.
Nadolol Nadolol The serum concentration of Nadolol can be increased when it is combined with Prochlorperazine.
Butorphanol Injection Butorphanol Injection The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Nalbuphine.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimethobenzamide.
Flavoxate Flavoxate Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Fluorouracil.
Colchicine Colchicine The metabolism of Prochlorperazine can be increased when combined with Colchicine.
Cephalexin Cephalexin The metabolism of Cephalexin can be decreased when combined with Prochlorperazine.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acetazolamide.
Ketoconazole Ketoconazole The metabolism of Prochlorperazine can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The metabolism of Thiotepa can be decreased when combined with Prochlorperazine.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Prochlorperazine.
Vinblastine Vinblastine The metabolism of Prochlorperazine can be decreased when combined with Vinblastine.
Metoprolol Metoprolol The metabolism of Metoprolol can be decreased when combined with Prochlorperazine.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Prochlorperazine.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.
Dicyclomine Dicyclomine Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Prochlorperazine.
Propantheline Propantheline Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Prochlorperazine.
Nifedipine Nifedipine The metabolism of Prochlorperazine can be increased when combined with Nifedipine.
Timolol Timolol The serum concentration of Timolol can be increased when it is combined with Prochlorperazine.
Verapamil Verapamil The metabolism of Prochlorperazine can be decreased when combined with Verapamil.
Atenolol Atenolol The serum concentration of Atenolol can be increased when it is combined with Prochlorperazine.
Pindolol Pindolol The serum concentration of Pindolol can be increased when it is combined with Prochlorperazine.
Etoposide Etoposide The metabolism of Prochlorperazine can be decreased when combined with Etoposide.
Glyburide Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Prochlorperazine.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Prochlorperazine.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Prochlorperazine.
Dicloxacillin Dicloxacillin The metabolism of Prochlorperazine can be increased when combined with Dicloxacillin.
Nafcillin Injection Nafcillin Injection The metabolism of Prochlorperazine can be increased when combined with Nafcillin.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Pentamidine.
Labetalol Labetalol The serum concentration of Labetalol can be increased when it is combined with Prochlorperazine.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prochlorperazine.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Prochlorperazine.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Prochlorperazine.
Buspirone Buspirone The metabolism of Buspirone can be decreased when combined with Prochlorperazine.
Lovastatin Lovastatin The metabolism of Prochlorperazine can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ciprofloxacin.
Fluoxetine Fluoxetine The serum concentration of Fluoxetine can be increased when it is combined with Prochlorperazine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Prochlorperazine.
Clozapine Clozapine The metabolism of Prochlorperazine can be decreased when combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.
Idarubicin Idarubicin The metabolism of Idarubicin can be decreased when combined with Prochlorperazine.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ofloxacin.
Didanosine Didanosine Prochlorperazine may increase the neurotoxic activities of Didanosine.
Clarithromycin Clarithromycin The metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Prochlorperazine.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Prochlorperazine.
Teniposide Injection Teniposide Injection The metabolism of Prochlorperazine can be decreased when combined with Teniposide.
Itraconazole Itraconazole The metabolism of Prochlorperazine can be decreased when combined with Itraconazole.
Atovaquone Atovaquone The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Prochlorperazine.
Rifabutin Rifabutin The metabolism of Prochlorperazine can be increased when combined with Rifabutin.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Prochlorperazine.
Bisoprolol Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Prochlorperazine.
Zolpidem Zolpidem Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The metabolism of Doxazosin can be decreased when combined with Prochlorperazine.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Prochlorperazine.
Omeprazole Omeprazole The metabolism of Prochlorperazine can be increased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Prochlorperazine can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The metabolism of Prochlorperazine can be decreased when combined with Venlafaxine.
Stavudine Stavudine Prochlorperazine may increase the neurotoxic activities of Stavudine.
Famciclovir Famciclovir The metabolism of Prochlorperazine can be decreased when combined with Famciclovir.
Fluvoxamine Fluvoxamine The metabolism of Prochlorperazine can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The metabolism of Nefazodone can be decreased when combined with Prochlorperazine.
Lamotrigine Lamotrigine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Prochlorperazine.
Tramadol Tramadol The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Prochlorperazine can be decreased when combined with Vinorelbine.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Prochlorperazine.
Lansoprazole Lansoprazole The metabolism of Prochlorperazine can be increased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Prochlorperazine can be decreased when combined with Ifosfamide.
Nicardipine Nicardipine The metabolism of Prochlorperazine can be decreased when combined with Nicardipine.
Bupropion Bupropion The metabolism of Bupropion can be decreased when combined with Prochlorperazine.
Ticlopidine Ticlopidine The metabolism of Prochlorperazine can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The metabolism of Saquinavir can be decreased when combined with Prochlorperazine.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Riluzole.
Glimepiride Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Prochlorperazine.
Ritonavir Ritonavir The serum concentration of Prochlorperazine can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Prochlorperazine can be decreased when combined with Docetaxel.
Clomipramine Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Prochlorperazine.
Zafirlukast Zafirlukast The metabolism of Prochlorperazine can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Prochlorperazine.
Pramipexole Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Prochlorperazine.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Donepezil.
Nelfinavir Nelfinavir The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Prochlorperazine.
Carvedilol Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Prochlorperazine.
Selegiline Selegiline The therapeutic efficacy of Selegiline can be decreased when used in combination with Prochlorperazine.
Bicalutamide Bicalutamide The metabolism of Prochlorperazine can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertraline.
Propafenone Propafenone The metabolism of Prochlorperazine can be decreased when combined with Propafenone.
Raloxifene Raloxifene The metabolism of Prochlorperazine can be decreased when combined with Raloxifene.
Irbesartan Irbesartan The metabolism of Prochlorperazine can be decreased when combined with Irbesartan.
Tamsulosin Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Prochlorperazine.
Ropinirole Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Prochlorperazine.
Quetiapine Quetiapine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Prochlorperazine.
Paroxetine Paroxetine The metabolism of Paroxetine can be decreased when combined with Prochlorperazine.
Tolcapone Tolcapone The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Tolcapone.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Prochlorperazine.
Efavirenz Efavirenz The metabolism of Prochlorperazine can be decreased when combined with Efavirenz.
Sildenafil Sildenafil The metabolism of Prochlorperazine can be decreased when combined with Sildenafil.
Celecoxib Celecoxib The metabolism of Prochlorperazine can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Prochlorperazine can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Prochlorperazine.
Thalidomide Thalidomide Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Aluminum Hydroxide Aluminum Hydroxide Aluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nateglinide Nateglinide The metabolism of Nateglinide can be decreased when combined with Prochlorperazine.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Prochlorperazine.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.
Rabeprazole Rabeprazole The metabolism of Prochlorperazine can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Prochlorperazine can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists